CALCA and migraine disorder: The average number of monthly migraine days at 3 months of treatment with an anti-CGRP-mAb was reported by just thirteen studies, at 6 months by eleven studies, none reported at 9 months of treatment, while four reported average monthly migraine days after 12 months of treatment.